Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention

WOBURN, MA / ACCESSWIRE / May 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that as part of several Skin Cancer Awareness Month activities taking place throughout the month of May, it is collaborating with The Skin Cancer Foundation to support sun safety awareness and educate the public on pre-cancer and skin cancer prevention, early detection and effective treatment.

A key to skin cancer prevention is diagnosing and treating the most common pre-cancer, actinic keratosis (AK). Biofrontera is working closely with the Foundation to help raise awareness of AK, a disease that affects 58 million Americans and, left untreated, may develop into squamous cell carcinoma, a life-threatening skin cancer. AK forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun and/or indoor tanning. Education and awareness are high priorities for both organizations and are essential to minimize this preventable disease. As part of this effort, this year The Skin Cancer Foundation designated May 17 as the day to focus on awareness of AK as a pre-cancer during their Skin Cancer Awareness Month activities.

The Skin Cancer Foundation is also holding its signature fundraising event, the annual Champions for Change Gala, in New York City on May 10, 2023. Each year, the Foundation honors Champions for Change - the individuals and/or corporate supporters committed to the organization's goal of changing behaviors and saving lives through skin cancer education. As a "Glow Guardian"-level sponsor, Biofrontera is making a meaningful investment in The Skin Cancer Foundations' lifesaving educational campaigns, community programs and research initiatives. Biofrontera will be hosting several key opinion leaders at this year's Gala.

"We're grateful to Biofrontera not only for their investment in our lifesaving work, but also for their commitment to raising awareness of AK and squamous cell carcinoma, which affect millions of Americans," said Deborah S. Sarnoff, MD, president of The Skin Cancer Foundation and a practicing dermatologist. "Our message is clear: Detecting an actinic keratosis early gives you the opportunity to treat the lesion and prevent skin cancer before it starts. If you see anything new, changing or unusual on your skin, make an appointment with a dermatologist right away."

"Biofrontera is proud to be supporting these important initiatives to help prevent skin cancer before it starts," said Erica Monaco, Chief Executive Officer of Biofrontera Inc. "Since our founding, Biofrontera has been dedicated to improving the treatment of AK. We believe that heightened awareness of AK and treatment with our Ameluz^®-PDT therapy, when necessary, can help patients and improve lives."

About The Skin Cancer Foundation 

The Skin Cancer Foundation is a nonprofit organization dedicated to public education about the prevention, early detection and treatment of skin cancer. The Foundation saves and improves lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. Its mission is to decrease the incidence of skin cancer through public and professional education and research. Since its inception in 1979, the Foundation has recommended following a complete sun protection regimen that includes seeking shade and covering up with clothing, including a wide-brimmed hat and UV-blocking sunglasses, in addition to daily sunscreen use. For more information, visit  https://www.skincancer.org.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

Forward-looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the growth strategy for Biofrontera Inc.'s (the "Company") Ameluz^®-PDT, improved market opportunities, educational outreach efforts, growth of the Company's salesforce and its sales territories and the impact of expanding the Company's salesforce on growth. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz^® in combination with BF-RhodoLED^® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz^® in combination with BF-RhodoLED^® is consistent with the Company's expectations; the Company's ability to comply with public company requirements; the Company's ability to regain compliance with Nasdaq continued listing standards, the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company's filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Contact:

LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com

SOURCE: Biofrontera Inc.